In recent decades, numerous molecular-targeted agents, such as Epidermal Growth Factor Receptor (EGFR), Tropomyosin Receptor Kinase (TRK), Vascular Endothelial Growth Factor Receptor (VEGFR), and Anaplastic Lymphoma Kinase (ALK), have exhibited remarkable antitumor efficacy across various tumor types, including CRC [24–27]. This evidence concerns the gene EGFR and colorectal carcinoma.